AMW Strengthens Executive Leadership Team by Appointing Wolfram E. Scholl as Chief Operating Officer
Warngau, Germany, September 2, 2025
AMW GmbH, a specialty pharmaceutical company focused on biodegradable controlled-release drug delivery systems, today announced the appointment of Wolfram E. Scholl as Chief Operating Officer (COO) as of September 1, 2025. As long-standing expert and consultant in supply chain management, he is responsible for production, quality, supply chain, engineering and operational excellence at AMW.
“Wolfram’s appointment comes at a pivotal time for our company,” commented Philipp Karbach, CEO and shareholder of AMW. “We are vigorously pursuing our plans to expand production capacity and are therefore particularly pleased to welcome Wolfram to our executive leadership team. As a recognized expert with international industry experience, both with in-house positions and in strategic and operational consulting, he will make a decisive contribution to achieving our ambitious growth targets.”
“I am delighted to contribute to shaping AMW in this exciting phase of the company’s development,” added Wolfram E. Scholl, COO of AMW. “Having already worked with some of my colleagues in an advisory capacity, I am absolutely convinced of AMW’s momentum and growth trajectory. I look forward to contributing to the company’s success, thus supporting AMW in its mission to provide as many patients as possible with access to value-added medicines.”
Mr. Scholl is a long-standing professional in the field of supply chain management with international leadership experience. In 2005 he founded S-CM Scholl-Consulting Munich, with a focus on cross-industry consulting for operations management and supply chain management. Previously, he was a partner at Arthur D. Little, where his responsibilities included supply chain management. Over the past 30 years, he has supported companies across a wide range of industries and countries in designing and implementing more than 90 complex projects with interdisciplinary teams. As an experienced consultant, he combines fact-based analysis with pragmatism and a strong focus on implementation.
Information about the AMW management team can also be found on our website at: https://amw-pharmaceuticals.com/en/about-us/#management.
###
About AMW GmbH:
AMW is a specialty pharmaceutical company focused on biodegradable implants, providing patients and partners access to value-added medicines for improved adherence and cost-effective therapies. The Company covers the entire value chain, from (co-)development to manufacturing and international commercialization.
AMW has two approved medical products: implants releasing goserelin or leuprorelin respectively, which are distributed worldwide via direct sales and out-licensing. In Germany, leuprorelin is marketed as Leugon® by AMW’s fully owned subsidiary Endomedica GmbH. Based on its unparalleled expertise in formulation development, the Company collaborates with pharma and biotech partners worldwide to develop and manufacture high-quality products and life-cycle solutions.
AMW is based in Warngau near Munich, Germany.
For further information please contact:
AMW GmbH
Eva Hoffmann
Phone: +49 8024 470999-0
E-mail: news@amw-pharmaceuticals.com